Trial · NCT06860633
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
NCT06860633, Phase 4, Recruiting, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod. Trials, record NCT06860633. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06860633
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
- NCT number
- NCT06860633
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
- Interventions
- Efgartigimod
- First posted
- 2025-03-06
- Last updated
- 2025-07-11
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 11 | Baseline, Day 11 | The Quantitative Myasthenia Gravis (QMG) is a scoring system that quantifies disease severity by measuring ocular, bulbar, respiratory and limb strength. The total scores range from 0 to 39, with higher scores indicating greater disease severity. |
| Secondary | Percentage of participants requiring rescue therapy with Plasma Exchange (PLEX) or Intravenous Immunoglobulin (IVIG) | During hospitalization, approximately 7 days | Number of participants requiring rescue therapy with Plasma Exchange (PLEX) or Intravenous Immunoglobulin (IVIG) over number of total participants |
| Secondary | Change from baseline in Myasthenia Gravis Activities of Daily Life (MG-ADL) scale at day 18 | Baseline, Day 18 | The Myasthenia Gravis Activities of Daily Life (MG-ADL) is a questionnaire administered verbally that measures MG symptoms and functional activities related to activities of daily living. The summative total scores range from 0 to 24, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Activities of Daily Life (MG-ADL) scale at day 32 | Baseline, Day 32 | The Myasthenia Gravis Activities of Daily Life (MG-ADL) is a questionnaire administered verbally that measures MG symptoms and functional activities related to activities of daily living. The summative total scores range from 0 to 24, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Manual Muscle Test (MG-MMT) at day 11 | Baseline, Day 11 | The Myasthenia Gravis Manual Muscle Test (MG-MMT) is an assessment that assigns numerical values to the presence of mild, moderate or severe weakness for specific muscle groups that may be affected by MG. The summative total scores range from 0 to 120, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Manual Muscle Test (MG-MMT) at day 18 | Baseline, Day 18 | The Myasthenia Gravis Manual Muscle Test (MG-MMT) is an assessment that assigns numerical values to the presence of mild, moderate or severe weakness for specific muscle groups that may be affected by MG. The summative total scores range from 0 to 120, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Manual Muscle Test (MG-MMT) at day 32 | Baseline, Day 32 | The Myasthenia Gravis Manual Muscle Test (MG-MMT) is an assessment that assigns numerical values to the presence of mild, moderate or severe weakness for specific muscle groups that may be affected by MG. The summative total scores range from 0 to 120, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) at day 18 | Baseline, Day 18 | The Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) is a scale that measures perceived limitations to fifteen different activities due to MG. Individual items are score 0 (not at all) to 4 (quite a bit). The summative total scores range from 0 to 60, with higher scores representing worse quality of life. |
| Secondary | Change from baseline in Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) at day 32 | Baseline, Day 32 | The Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) is a scale that measures perceived limitations to fifteen different activities due to MG. Individual items are score 0 (not at all) to 4 (quite a bit). The summative total scores range from 0 to 60, with higher scores representing worse quality of life. |
| Secondary | Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 4 | Baseline, Day 4 | The Quantitative Myasthenia Gravis (QMG) is a scoring system that quantifies disease severity by measuring ocular, bulbar, respiratory and limb strength. The total scores range from 0 to 39, with higher scores indicating greater disease severity. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers27
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06860633
GET https://conductscience.org/api/trials/v1/NCT06860633/papers?page=2